Articles tagged with Atopic Dermatitis
A new Finnish study found that a green living environment in early childhood does not prevent eczema, despite previous expectations. The study associated coniferous forests and agricultural areas with an elevated risk of eczema, particularly for children born in the spring.
Researchers tracked the evolution of Staphylococcus aureus in patients with eczema, discovering rapid mutations in a gene that enables the bacteria to grow faster on the skin. These findings could lead to targeted treatments by targeting variants of S. aureus associated with eczema symptoms.
A large UK Biobank study found that poor sleep quality may bolster genetic susceptibility to asthma, potentially doubling the risk. A healthy sleep pattern was associated with a lower risk of asthma, and spotting and treating sleep disorders early on might lessen the risks.
Research published in Annals of the Rheumatic Diseases found that people with atopic diseases like asthma or eczema are at a heightened risk of developing osteoarthritis. Drugs used to dampen down allergic reactions may help lessen this risk, suggesting a potential new approach to treating the condition.
A new study published in the New England Journal of Medicine found that lebrikizumab was effective in treating moderate to severe atopic dermatitis, improving skin clarity and reducing itching. The study involved two phase 3 trials with over 700 participants and showed promising results for the treatment.
A team of dermatologists developed an AI model to detect complications from bacterial or viral infections in atopic dermatitis patients. The model distinguishes between eczema and skin lesions caused by blood cancer, improving patient management and health outcomes.
A study found that individuals with a history of atopic diseases, such as allergic asthma or rhinitis, had significantly lower rates of melanoma and skin cancer compared to non-atopic individuals. The risk of melanoma was up to 50% lower in atopic patients, and the overall risk of skin cancer was also reduced.
Researchers at National Jewish Health have discovered biomarkers on the surface of infant skin that can predict the development of atopic dermatitis and other allergic conditions. The study's findings suggest that targeted therapies such as emollients or biologics may be effective in preventing eczema.
Eczema affects approximately 6% of children and adolescents worldwide, with a median prevalence rate of 3.5%. Researchers analyzed data from 14 countries involving over 74,000 adolescents and found an average increase in eczema symptoms of 0.98% per decade among adolescents and 1.21% per decade among children.
Researchers will use systems biology approach to identify biomarkers and mechanisms underlying food allergies and atopic dermatitis. The study aims to improve prevention, diagnosis, and clinical management of these conditions.
Researchers have developed a new peptide drug that silences genes responsible for skin inflammation, suppressing lesions and healing skin without side effects. The topical treatment is being tested in a clinical trial for patients with eczema, offering hope for more effective treatments.
Research by Uppsala University and Swedish University of Agricultural Sciences links atopic dermatitis in dogs to specific genome regions. The study identifies genes coinciding with human atopic eczema, including the filaggrin gene region.
Patients with moderate to severe atopic dermatitis showed significant improvement in signs and symptoms while taking rocatinlimab, a novel monoclonal antibody therapy. The treatment has the potential to change the genetic makeup of the disease, leading to lasting results without continued use.
Early application of skin moisturizers is an effective strategy for preventing atopic dermatitis (AD) in high-risk infants. A systematic review and network meta-analysis found that three types of emollients, including cream, emulsion, and mixed types, are comparable in preventing AD; however, emollient emulsion may be the optimal option.
Urban-living Indigenous children and young people in high-income countries are disproportionately affected by atopic dermatitis and bacterial skin infections, which can lead to serious complications. This systematic review highlights the need for co-designed research with Indigenous communities to address these health inequities.
Eczema affects 10-20% of Canadian infants, making it a common condition to manage. Optimally managing atopic dermatitis in infants is crucial, as it impacts the whole family.
Researchers highlight climate-sensitive dermatological manifestations initiated or exacerbated by floods, wildfires, and extreme heat events. These events disproportionately affect marginalized populations, exacerbating existing health disparities.
Researchers explored how differences in skin composition affect susceptibility to diseases like psoriasis and atopic dermatitis. The study found that body site determines skin structure and function, with specific lipids and proteins playing a crucial role in disease diagnosis.
A new biologic drug has been found to be highly effective in reducing the signs and symptoms of moderate-to-severe eczema in infants and young children. The study showed that more than half of treated children experienced a 75% reduction in eczema symptoms, leading to improved sleep and increased ability to lead normal lives.
Researchers identified an immune biomarker in newborns that can predict the onset and severity of pediatric atopic eczema. The Barrier dysfunction in Atopic newBorns (BABY) study found elevated levels of TARC at 2 months to be more than twice as likely to develop eczema by age 2.
This survey study examined associations between demographic and clinical variables and eczema burden in adults. Key findings include identifying factors contributing to eczema severity, which can inform targeted interventions.
A study has found that there is no single best moisturiser for children with eczema, highlighting the importance of patient education and choice. The trial, funded by the National Institute for Health and Care Research, compared four types of moisturisers and found that reactions were common regardless of type.
A new study reveals that allergic asthma is a significant risk factor for human cardiovascular diseases, with certain medications affecting heart health. Researchers found that inflammatory cells play a crucial role in both conditions and that targeting them may lead to better treatment options.
Researchers discovered that obesity changes molecular underpinnings of allergic inflammation in both mice and humans. The treatment in obese mice makes their skin worse instead of healing, but a specific drug can 'de-fatten' obese mice without changing body weight.
Researchers from the University of Pennsylvania and Oak Ridge National Laboratory have identified a cascade of inflammatory signaling that precedes skin ulcers in atopic dermatitis. A mouse model lacking an activator of NF-kB signaling led to the development of skin lesions, shedding light on the early stages of the condition.
Researchers found sublingual immunotherapy with house dust mite extract to be effective in reducing signs and symptoms of atopic dermatitis. The treatment, administered over 18 months, resulted in significant improvements in pruritus and lesions, with rare side effects.
Researchers identify eleven rare genetic variants associated with eczema, accounting for over 20% of the disease's heritability. The variants are found in genes that code for proteins involved in inflammatory reactions, providing promising targets for new therapeutic approaches.
A new study reveals that only 40% of parents received a recommendation to introduce peanut products by 11 months of age, despite the 2017 guidelines. The survey also found that most infants are at moderate- or low-risk for developing peanut allergies and can safely have peanut-containing foods introduced.
Researchers identified a bacterium on healthy cats that produces antibiotics against severe skin infections in humans and pets. The discovery may lead to new treatments for MRSP infections in dogs and potentially other inflammatory skin diseases.
A novel CXCR4 antagonist, EPI-X4 JM#21, has been developed to prevent atopic dermatitis and airway inflammation. The compound suppresses allergen-induced immune cell infiltration and prevents skin inflammation in mouse models.
Researchers investigated whether allergic diseases cause mental health conditions, finding little evidence of a causal relationship. The study used Mendelian Randomisation to identify genetic variants linked to allergies and mental health, but found no associations between the two.
Researchers identified a new cell type in human skin contributing to AD and psoriasis, highlighting potential therapeutic targets. The study revealed CD14+ type 3 dendritic cells co-producing IL1B and IL23A, essential for PSO pathogenesis.
Severe eczema was associated with symptoms of depression and internalizing behaviors throughout childhood and adolescence. The observational study included 11,000 children from the United Kingdom.
A pilot study from North Carolina State University found that a gene associated with autism spectrum disorder and pain hypersensitivity may decrease itch response. Contactin-associated protein 2 (CNTNAP2) is expressed in sensory neurons responsible for transmitting sensations of both pain and itch.
A clinical trial by Trinity College Dublin researchers has shown upadacitinib to be the most effective treatment for moderate-to-severe atopic dermatitis. The study involved 1,600 patients and found that the drug provides a substantial unmet need in treating this chronic inflammatory condition.
Researchers found that internet-delivered cognitive behavioral therapy (iCBT) significantly improves eczema symptoms and reduces stress, insomnia, and depression. The treatment required fewer therapy resources than conventional face-to-face psychological treatment, making it a potential care option for a large patient group.
A new wearable sensor can quantify itch by measuring scratching motions, providing a crucial tool for diagnosing and treating atopic dermatitis. The device's accuracy has been validated in pediatric patients, making it an exciting development for managing the condition.
A Swedish study of over 100,000 children found that early antibiotic exposure before birth and during the first year of life increases the risk of developing eczema. The research suggests a potential long-term consequence of antibiotic use on childhood skin health.
Etrasimod demonstrated clinically meaningful improvements in both clinical signs of atopic dermatitis and patient reported outcomes. The treatment group achieved statistical significance in the percentage change in weekly peak pruritis, Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM).
A study examined the association between short-term wildfire air pollution exposure and changes in eczema clinic visits and medications prescribed. The findings suggest a potential link between wildfire air pollution and eczema symptoms.
A new study found that short-term exposure to hazardous air quality from wildfire smoke can harm skin health, particularly for those with eczema. The research, conducted during the Camp Fire in 2018, saw a significant increase in patients visiting clinics with concerns of eczema and general itch.
A recent study investigates the association between eczema severity and risk of learning disabilities in children. The study found a significant link between the two, highlighting the importance of addressing eczema in pediatric care.
The Systems Biology of Early Atopy study aims to integrate biological, environmental, and genetic data to better understand the origins of allergic diseases in children. The 2,500-family study will examine prenatal and early childhood markers of high risk for food allergy and eczema.
Researchers have identified p62 as a multifunctional protein that influences inflammatory changes in diseased epidermis. Inhibiting p62 leads to alleviation of chronic inflammation, suggesting it as a promising therapeutic target for atopic dermatitis and psoriasis.
A new study has identified a universal strain of bacteria derived from healthy human skin that can treat the most common type of eczema. In a Phase I clinical trial, two-thirds of participants showed significant improvements in symptoms, including reduced itchiness and inflammation.
A new study found that people with severe atopic eczema have a higher risk of dying from health issues like infections, lung problems, and kidney or bladder disorders. The absolute risk of death was modest, but the findings suggest that those with severe or more active forms of the disease face a higher risk.
A study from WashU Medicine reveals that allergens in the environment trigger episodes of acute itch in eczema patients, which often don't respond to antihistamines. Researchers found a previously unrecognized pathway carrying itch signals to the brain, opening new avenues for treatment.
Researchers have discovered how Staphylococcus aureus binds to human corneocytes in atopic dermatitis, providing new insights into the development of targeted treatments.
Researchers found individuals with atopic dermatitis are more likely to have autoimmune skin and gastrointestinal diseases. The study, published in the British Journal of Dermatology, analyzed over 104,000 cases of atopic dermatitis and identified its association with various autoimmune conditions.
Black and Hispanic children in the US experience more severe eczema than their white counterparts. Additionally, they are less likely to report overall excellent health. The disparities exist due to differences in how the condition appears on diverse skin tones, requiring individualized treatment approaches.
A randomized controlled trial found that vitamin D supplementation improved clinical outcomes for children with severe atopic dermatitis. The study involved 86 patients who received either oral daily vitamin D or placebo for 12 weeks.
Research from the University of Pennsylvania School of Medicine found that TV ads for psoriasis and eczema medications lack diversity, particularly among racial and ethnic minorities. This underrepresentation may contribute to treatment disparities, as non-white patients are less likely to receive effective treatments.
An experimental probiotic treatment reduced eczema severity and improved quality of life for children as young as 3 years old. The treatment modified the skin microbiome and increased microbial diversity, reducing Staphylococcus aureus levels and promoting skin repair processes.
Two common gene variants in the KIF3A gene increase the risk of young children developing atopic dermatitis and food allergies. The study provides new insights into the genetic mechanisms underlying this condition, which affects up to 20% of all children.
Researchers found that two common genetic variations in the KIF3A gene impair skin barrier function, leading to increased water loss and development of atopic dermatitis. Genetic testing could help identify infants at risk, potentially preventing eczema and related allergic diseases.
A study of 552 older adults found 80% had at least one skin disease requiring treatment, with fungal infections and eczema being the most prevalent. The research also revealed that more than a third had multiple simultaneous skin diseases, highlighting the importance of whole body skin evaluations in this age group.
Scientists discovered that Staphylococcus epidermidis interacts with the immune system to promote wound healing and prevent inflammation. The study's findings may lead to therapies for conditions like atopic dermatitis and inflammatory bowel diseases, affecting millions worldwide.
A new study from Binghamton University connects lipids and bacteria to aid in understanding eczema. Researchers found that decreased levels of ceramides can allow Staphylococcus aureus bacteria to penetrate the skin barrier, leading to inflammation and infection. Further research is needed to unlock the secrets of atopic dermatitis.
Researchers at the University of British Columbia have discovered a key enzyme that contributes to eczema's debilitating effects, offering new hope for treatment. By inhibiting Granzyme B, the study suggests a safer and more effective long-term treatment could prevent skin damage and reduce symptoms.
A new study has discovered a link between gene defects and eczema, wheeze, and nasal blockage among babies as young as six months. The research suggests that treatment targeted towards children carrying these genetic defects started soon after birth could improve their lives.